Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors

Purpose Sorafenib and everolimus are both active against neuroendocrine tumors (NET). Because of potential synergy between VEGF pathway and mTOR inhibitors, we performed a phase I study to evaluate the safety and feasibility of combining sorafenib and everolimus in patients with advanced NET.